<DOC>
	<DOCNO>NCT01586507</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetic ( PK ) single oral dos ULTRAM Extended Release ( ER ) 2 dose level adolescent 12 17 year old , inclusive ( 17 year 364 day ) pain due injury nonmalignant disease , PK adult , respect PK parameter AUCâˆž ( area curve ) racemic tramadol . PK explore drug absorb body , distribute within body , remove body time .</brief_summary>
	<brief_title>A Study ULTRAM ER Two Dose Levels Adolescents With Pain</brief_title>
	<detailed_description>This multicenter , open-label ( people know identity intervention ) , 2-group , single dose study . Within group participant Parts 1 2 , least 1/3 participant female , least 1/3 participant male , least 1/3 participant age 14 year , least 1/3 participant age 16 year . Participants assign 1 group . Each group participant receive single oral dose ULTRAM ER 1 occasion . Group 1 receive dose ULTRAM ER close 2 mg/kg , base participant 's body weight adjust dose 25 mg increment . Following completion evaluation Group 1 , pharmacokinetic data evaluate target dose Group 2 achieve level exposure similar see single 200 mg ULTRAM ER dose adult . The maximum dose ULTRAM ER exceed 6 mg/kg 300 mg . When study physician , investigator , medical monitor agree PK drug well-characterized drug well tolerate , enrollment begin Group 2 study . The sponsor 's responsible Medical Officer evaluate safety calculate dose Group 2 participant evaluation adverse drug event pay particular attention event suggestive either opioid toxicity serotonin toxicity .</detailed_description>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Confirmed need control pain due injury nonmalignant disease influence fluid shift general drug disposition Weighs least 30 kg Female participant must premenarchal , surgically sterile , abstinent , , sexually active , practice effective method birth control Able swallow intact tablet aid water ( participant may chew , divide , dissolve , crush study drug ) Signed informed consent document indicate he/she understands purpose procedure require study willing participate study Informed consent sign parent ( ) legal guardian ( ) participant History current clinically significant medical illness condition include ( limited ) cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , significant pulmonary disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness condition investigator considers exclude participant could interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pain</keyword>
	<keyword>ULTRAM ER</keyword>
	<keyword>Tramadol hydrochloride</keyword>
	<keyword>Adolescents</keyword>
</DOC>